ResMed Inc. (NYSE:RMD) – Equities research analysts at William Blair lowered their Q2 2019 EPS estimates for shares of ResMed in a research report issued to clients and investors on Thursday, November 15th. William Blair analyst M. Kaczor now expects that the medical equipment provider will post earnings of $0.93 per share for the quarter, down from their prior estimate of $0.94.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 25th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.80 by $0.01. ResMed had a net margin of 13.94% and a return on equity of 26.29%. The firm had revenue of $588.28 million during the quarter, compared to analyst estimates of $576.66 million.

A number of other equities research analysts have also issued reports on the stock. BMO Capital Markets upped their price objective on shares of ResMed from $107.00 to $109.00 and gave the company a “market perform” rating in a report on Friday, October 26th. Credit Suisse Group raised shares of ResMed from a “neutral” rating to an “outperform” rating in a report on Friday, October 26th. Finally, Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $114.50.

Shares of RMD opened at $101.61 on Monday. The company has a quick ratio of 1.91, a current ratio of 2.58 and a debt-to-equity ratio of 0.27. ResMed has a 12-month low of $82.81 and a 12-month high of $116.64. The stock has a market capitalization of $14.85 billion, a P/E ratio of 28.78, a PEG ratio of 2.66 and a beta of 0.97.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Morgan Stanley lifted its position in ResMed by 30.2% in the second quarter. Morgan Stanley now owns 966,736 shares of the medical equipment provider’s stock valued at $100,135,000 after buying an additional 223,963 shares during the last quarter. Pillar Pacific Capital Management LLC lifted its position in shares of ResMed by 1.6% during the third quarter. Pillar Pacific Capital Management LLC now owns 46,546 shares of the medical equipment provider’s stock worth $5,368,000 after purchasing an additional 744 shares in the last quarter. Motley Fool Asset Management LLC lifted its position in shares of ResMed by 0.8% during the second quarter. Motley Fool Asset Management LLC now owns 202,522 shares of the medical equipment provider’s stock worth $20,977,000 after purchasing an additional 1,522 shares in the last quarter. Stephens Investment Management Group LLC lifted its position in shares of ResMed by 1.0% during the second quarter. Stephens Investment Management Group LLC now owns 360,961 shares of the medical equipment provider’s stock worth $37,567,000 after purchasing an additional 3,463 shares in the last quarter. Finally, Motley Fool Wealth Management LLC lifted its position in shares of ResMed by 1.7% during the second quarter. Motley Fool Wealth Management LLC now owns 181,025 shares of the medical equipment provider’s stock worth $18,751,000 after purchasing an additional 2,940 shares in the last quarter. 65.61% of the stock is currently owned by institutional investors.

In other ResMed news, insider James Hollingshead sold 600 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $115.88, for a total value of $69,528.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Brett Sandercock sold 2,000 shares of the company’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $114.30, for a total transaction of $228,600.00. Following the completion of the transaction, the chief financial officer now directly owns 73,232 shares in the company, valued at approximately $8,370,417.60. The disclosure for this sale can be found here. Insiders sold 20,027 shares of company stock worth $2,136,094 in the last ninety days. 1.24% of the stock is currently owned by corporate insiders.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 13th. Shareholders of record on Thursday, November 8th will be given a $0.37 dividend. The ex-dividend date is Wednesday, November 7th. This represents a $1.48 dividend on an annualized basis and a yield of 1.46%. ResMed’s payout ratio is currently 41.93%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Further Reading: Dividend Aristocrat Index

Earnings History and Estimates for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.